Table 4.
Incidence rate ratios and estimated number of excess events per million for individual outcomes in the 1–42 days following vaccination or a SARS-CoV-2 positive test (before or after vaccination) compared to baseline period in adolescents aged 12-17 years
| BNT162b2 vaccine | mRNA-1273 vaccine | ChAdOX1 vaccine | Positive SARS-CoV-2 test | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | IRR (95% CI) | Excess events (95% CI) | N | IRR (95% CI) | Excess events (95% CI) | N | IRR (95% CI) | Excess events (95% CI) | N | IRR (95% CI) | Excess events (95% CI) | |
| Multisystem inflammatory syndrome | ||||||||||||
| First dose/positive test (before vaccine) | 21 | 0.76 (0.43, 1.37) | 0 | 0 | - | - | 0 | - | - | 98 | 12.38 (8.88, 17.28) | 84 (81, 86) |
| Second dose/positive test (after vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | < 5 | - | - |
| Third dose | < 5 | - | - | 0 | - | - | 0 | - | - | |||
| Myocarditis | ||||||||||||
| First dose/positive test (before vaccine) | 19 | 1.92 (1.08, 3.43) | 3 (0, 5) | 0 | - | - | <5 | - | - | 7 | 3.17 (1.34, 7.50) | 4 (2, 6) |
| Second dose/positive test (after vaccine) | 17 | 2.96 (1.65, 5.32) | 5 (3, 6) | 0 | - | - | 0 | - | - | < 5 | - | - |
| Third dose | < 5 | - | - | < 5 | - | - | 0 | - | - | |||
| Immune or idiopathic thrombocytopenia | ||||||||||||
| First dose/positive test (before vaccine) | 41 | 0.76 (0.55, 1.07) | 0 | 0 | - | - | <5 | - | - | 37 | 1.79 (1.26, 2.54) | 15 (7, 21) |
| Second dose/positive test (after vaccine) | 31 | 0.83 (0.57, 1.21) | 0 | 0 | - | - | <5 | - | - | 6 | 1.64 (0.72, 3.74) | 0 |
| Third dose | 10 | 0.72 (0.37, 1.37) | 0 | < 5 | - | - | 0 | - | - | |||
| Epilepsy | ||||||||||||
| First dose/positive test (before vaccine) | 215 | 1.02 (0.88, 1.18) | 0 | 0 | - | - | 15 | 1.93 (1.10, 3.39) | 705 (129, 1033) | 77 | 1.29 (1.02, 1.64) | 16 (2, 28) |
| Second dose/positive test (after vaccine) | 190 | 1.17 (1.00, 1.37) | 12 (0, 23) | < 5 | - | - | 9 | 1.19 (0.59, 2.41) | - | 22 | 1.58 (1.03, 2.42) | 15 (1, 24) |
| Third dose | 48 | 0.83 (0.62, 1.13) | 0 | 6 | 0.95 (0.38, 2.36) | 0 | 0 | - | - | |||
| Acute pancreatitis | ||||||||||||
| First dose/positive test (before vaccine) | 28 | 1.25 (0.82, 1.92) | 0 | 0 | - | - | <5 | - | - | 7 | 1.04 (0.47, 2.27) | 0 |
| Second dose/positive test (after vaccine) | 10 | 0.65 (0.34, 1.25) | 0 | 0 | - | - | 0 | - | - | < 5 | - | - |
| Third dose | 5 | 0.87 (0.34, 2.20) | 0 | 0 | - | - | 0 | - | - | |||
| Myositis | ||||||||||||
| First dose/positive test (before vaccine) | 7 | 1.20 (0.53, 2.75) | 0 | 0 | - | - | 0 | - | - | < 5 | - | - |
| Second dose/positive test (after vaccine) | < 5 | - | - | 0 | - | - | <5 | - | - | 0 | - | - |
| Third dose | < 5 | - | - | 0 | - | - | 0 | - | - | |||
| Acute disseminated encephalomyelitis | ||||||||||||
| First dose/positive test (before vaccine) | 5 | 0.61 (0.24, 1.56) | 0 | 0 | - | - | 0 | - | - | 6 | 1.29 (0.55, 3.02) | 0 |
| Second dose/positive test (after vaccine) | 8 | 1.46 (0.67, 3.18) | 0 | 0 | - | - | 0 | - | - | < 5 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Demyelinating disease | ||||||||||||
| First dose/positive test (before vaccine) | 7 | 0.85 (0.38, 1.89) | 0 | 0 | - | - | 0 | - | - | < 5 | - | - |
| Second dose/positive test (after vaccine) | 9 | 1.55 (0.75, 3.21) | 0 | 0 | - | - | 0 | - | - | < 5 | - | - |
| Third dose | < 5 | - | - | 0 | - | - | 0 | - | - | |||
| Appendicitis | ||||||||||||
| First dose/positive test (before vaccine) | 461 | 0.90 (0.81, 1.00) | 0 | 0 | - | - | < 5 | - | - | 209 | 1.07 (0.93, 1.24) | 0 |
| Second dose/positive test (after vaccine) | 330 | 0.89 (0.79, 1.01) | 0 | 0 | - | - | 6 | 4.64 (1.77, 12.17) | 512 (283, 599) | 26 | 0.80 (0.54, 1.19) | 0 |
| Third dose | 64 | 1.04 (0.80, 1.35) | 0 | 9 | 1.27 (0.64, 2.52) | 0 | 0 | - | - | |||
| Guillain-Barre Syndrome | ||||||||||||
| First dose/positive test (before vaccine) | <5 | - | - | 0 | - | - | 0 | - | - | 5 | - | - |
| Second dose/positive test (after vaccine) | <5 | - | - | 0 | - | - | 0 | - | - | <5 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Angioedema | ||||||||||||
| First dose/positive test (before vaccine) | 25 | 1.40 (0.89, 2.19) | 0 | 0 | - | - | < 5 | - | - | 11 | 1.46 (0.77, 2.76) | 0 |
| Second dose/positive test (after vaccine) | 12 | 0.91 (0.50, 1.68) | 0 | 0 | - | - | < 5 | - | - | < 5 | - | - |
| Third dose | < 5 | - | - | < 5 | - | - | 0 | - | - | |||
| Anaphylaxis | ||||||||||||
| First dose/positive test (before vaccine) | 44 | 1.33 (0.94, 1.87) | 0 | 0 | - | - | 0 | - | - | 19 | 1.50 (0.92, 2.42) | 0 |
| Second dose/positive test (after vaccine) | 21 | 0.85 (0.54, 1.34) | 0 | 0 | - | - | 0 | - | - | <5 | - | - |
| Third dose | 7 | 1.26 (0.57, 2.79) | 0 | <5 | - | - | 0 | - | - | |||
N Number of events, IRR Incidence rate ratio, CI Confidence interval.